Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Luc-Matthieu ForneckerJulien LazaroviciIgor AurerRené-Olivier CasasnovasAnne-Claire GacChristophe BonnetKrimo BouabdallahPierre FeugierLena SpechtLysiane MolinaMohamed TouatiCécile BorelAspassia StamatoullasEmmanuelle Nicolas-VirelizierLaurent PascalPieternella J LugtenburgNicola Di RenzoThierry Vander BorghtAlexandra Traverse-GlehenPeggy DartiguesMartin HutchingsAnnibale VersariMichel MeignanMassimo FedericoMarc Andrénull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.
Keyphrases
- hodgkin lymphoma
- open label
- early stage
- phase iii
- phase ii
- double blind
- clinical trial
- phase ii study
- lps induced
- pet ct
- lipopolysaccharide induced
- study protocol
- positron emission tomography
- placebo controlled
- computed tomography
- sentinel lymph node
- cross sectional
- pet imaging
- inflammatory response
- randomized controlled trial
- squamous cell carcinoma